CHRAC1 (Chromatin Accessibility Complex Protein 1): A Comprehensive Review

Introduction

CHRAC1 (Chromatin Accessibility Complex Subunit 1), also known as CHRAC-15, HuCHRAC15, or YCL1, is a small histone-fold protein that functions as an essential component of the chromatin accessibility complex (CHRAC) in humans. Encoded by the CHRAC1 gene (gene ID: 54108) located on chromosome 8q24.3, this 131 amino acid protein (UniProt: Q9NRG0) plays a critical role in ATP-dependent chromatin remodeling by facilitating nucleosome sliding and assembly. CHRAC1 forms a stable heterodimer with POLE3 (CHRAC-17/p17) that binds DNA in a sequence-independent manner and integrates into larger chromatin remodeling complexes. Through its interactions with the ISWI-family ATPase SMARCA5/SNF2H and the regulatory subunit BAZ1A/ACF1, CHRAC1 participates in fundamental nuclear processes including DNA replication, transcriptional regulation, and chromatin organization [poot-2000-huchrac-abstract][kukimoto-2004-chrac15-17-sliding-abstract].

The identification of CHRAC1 emerged from studies of chromatin remodeling complexes in Drosophila melanogaster, where the chromatin accessibility complex was first discovered as an ATP-dependent machine capable of increasing DNA accessibility within chromatin [vargaweisz-1997-chrac-nature-abstract]. Subsequent work by Poot and colleagues in 2000 characterized the human homolog, HuCHRAC, and identified two novel histone-fold proteins, p15 (CHRAC1) and p17 (POLE3), as conserved subunits [poot-2000-huchrac-abstract]. This evolutionary conservation from insects to humans underscores the fundamental importance of CHRAC1 in chromatin biology.

Protein Structure and Domain Architecture

CHRAC1 is a relatively small protein consisting of 131 amino acids with an apparent molecular mass of approximately 15 kDa as determined by SDS-PAGE analysis [poot-2000-huchrac-abstract]. The protein contains a central histone-fold domain (HFD) of approximately 65 amino acids, flanked by short N-terminal and C-terminal regions that are enriched in acidic and lysine residues [bolognese-2000-ybl1-ycl1-abstract]. The histone-fold domain of CHRAC1 is classified as an H2A-type fold, showing significant similarity to the HFD found in NFYC (NF-YC, CBFC), a subunit of the CCAAT-binding transcription factor NF-Y [corona-2000-chrac14-16-abstract][gnesutta-2013-hfd-proteins-abstract].

The crystal structure of the Drosophila CHRAC14-CHRAC16 heterodimer (homologs of human POLE3 and CHRAC1, respectively) was determined at 2.4-Angstrom resolution by Hartlepp and colleagues in 2005 (PDB: 2BYM) [hartlepp-2005-structure-mechanism-abstract]. This structure revealed that the two proteins dimerize via a variant histone fold in a characteristic "handshake" configuration, directly analogous to the H2A-H2B histone pair within the nucleosome. The heterodimer contains unstructured N- and C-terminal tail domains that protrude from the handshake structure, reminiscent of histone tails. Importantly, deletion of the negatively charged C-terminus of CHRAC-16 (the fly homolog of CHRAC1) enhances DNA binding 25-fold but paradoxically inhibits nucleosome sliding, suggesting that these terminal regions play crucial regulatory roles in balancing DNA binding affinity with functional activity [hartlepp-2005-structure-mechanism-abstract].

Despite sharing only 15-18% sequence identity with core histones H2A and H2B, CHRAC1 and related histone-fold domain proteins share highly conserved tertiary structures [gnesutta-2013-hfd-proteins-abstract]. The CHRAC1 HFD shows 25-35% sequence identity with other H2A-type HFD proteins including NC2alpha, NF-YC, and CHRAC-16, which is considerably higher than the identity with canonical histones. This structural conservation enables the CHRAC1-POLE3 heterodimer to function in a manner analogous to DNA chaperones, providing transient acceptor sites for DNA during the nucleosome remodeling process.

Molecular Function: Facilitation of Nucleosome Sliding and Assembly

The primary molecular function of CHRAC1 is to facilitate ATP-dependent nucleosome sliding and chromatin assembly as a component of the CHRAC complex. This function was definitively established through biochemical studies by Kukimoto and colleagues in 2004, who demonstrated that the CHRAC-15/17 (CHRAC1/POLE3) heterodimer enhances nucleosome sliding mediated by the ACF complex (ACF1-ISWI) [kukimoto-2004-chrac15-17-sliding-abstract]. The direct interaction between CHRAC-15/17 and ACF1 is essential for this enhancement, and notably, CHRAC-15 (CHRAC1) specifically is required for the interaction with ACF and the resulting enhancement of nucleosome sliding activity.

The mechanism by which CHRAC1 facilitates nucleosome sliding involves low-affinity, sequence-independent DNA binding. The CHRAC1-POLE3 heterodimer binds naked DNA with submicromolar affinity but does not bind to nucleosomes directly [poot-2000-huchrac-abstract]. This DNA binding activity is thought to provide a transient acceptor site for DNA that is being displaced from the histone surface during the sliding reaction [hartlepp-2005-structure-mechanism-abstract]. Analysis of the DNA binding properties suggests that CHRAC1-POLE3 functions analogously to the DNA chaperone HMGB1 in facilitating nucleosome remodeling, where dynamic, low-affinity DNA interactions improve the efficiency of nucleosome mobilization [hartlepp-2005-structure-mechanism-abstract].

Mechanistically, CHRAC induces movements of intact histone octamers to neighboring DNA segments without disrupting the octamer or displacing histones to competing DNA in trans [langst-1999-nucleosome-movement-abstract]. This nucleosome sliding activity is ATP-dependent and requires the catalytic activity of the ISWI ATPase (SMARCA5/SNF2H in humans). Importantly, the directionality of nucleosome sliding differs between CHRAC and ISWI alone, indicating that the accessory subunits including CHRAC1 modulate the activity of the ATPase motor [langst-1999-nucleosome-movement-abstract].

Beyond nucleosome sliding, CHRAC1 also participates in chromatin assembly reactions. The CHRAC-15/17 complex facilitates ACF-mediated chromatin assembly, converting irregular chromatin into regular arrays of nucleosomes with even spacing [vargaweisz-1997-chrac-nature-abstract][kukimoto-2004-chrac15-17-sliding-abstract]. Interestingly, this chromatin assembly activity occurs through a mechanism distinct from nucleosome sliding enhancement, suggesting that CHRAC1 has multiple functional modes in chromatin dynamics.

The CHRAC Complex: Composition and Organization

The complete human CHRAC (HuCHRAC) complex consists of four core subunits: SMARCA5/SNF2H (the ISWI ATPase), BAZ1A/ACF1 (the regulatory subunit), CHRAC1/CHRAC-15 (p15), and POLE3/CHRAC-17 (p17) [poot-2000-huchrac-abstract]. SMARCA5 provides the ATP-dependent motor activity that drives nucleosome sliding, while ACF1 contains multiple functional domains including WAC, DDT, WAKZ, PHD finger, and bromodomain motifs that regulate nucleosome interactions and targeting [fyodorov-2004-acf1-chromatin-abstract]. The CHRAC1-POLE3 heterodimer binds DNA and enhances the efficiency of the remodeling reaction.

The evolutionary conservation of this complex is remarkable. In Drosophila, CHRAC contains ISWI, Acf1, CHRAC-14 (homolog of POLE3), and CHRAC-16 (homolog of CHRAC1) [corona-2000-chrac14-16-abstract]. Notably, Drosophila CHRAC also contains topoisomerase II as a fifth subunit, which was not found in human CHRAC [vargaweisz-1997-chrac-nature-abstract][poot-2000-huchrac-abstract]. This compositional difference may reflect species-specific functional requirements.

CHRAC is closely related to but distinct from the ACF complex, which contains only SMARCA5 and ACF1 without the histone-fold subunits [fyodorov-2004-acf1-chromatin-abstract]. The presence of CHRAC1 and POLE3 in CHRAC distinguishes it from ACF and confers enhanced nucleosome sliding activity. Both complexes participate in chromatin assembly and remodeling, but CHRAC appears to be particularly important for efficient nucleosome mobilization under conditions of limiting enzyme concentrations [hartlepp-2005-structure-mechanism-abstract].

Dual Identity: CHRAC Subunit and DNA Polymerase Epsilon Component

A remarkable feature of the CHRAC histone-fold subunits is their dual localization in distinct macromolecular complexes. POLE3 (CHRAC-17/p17) was independently identified as a subunit of human DNA polymerase epsilon [li-2000-pole3-pole4-abstract]. Within the polymerase epsilon complex, POLE3 forms a heterodimer with POLE4 (p12), and this heterodimer is required for interaction with the catalytic subunit POLE1 (p261) and the accessory subunit POLE2 (p59) [li-2000-pole3-pole4-abstract]. This dual residence of POLE3 in both chromatin remodeling (with CHRAC1) and DNA replication (with POLE4) machineries suggests functional coordination between these processes.

CHRAC1 also interacts with POLE3 in the context of the DNA polymerase epsilon complex pathway, though its role there is less well characterized than in CHRAC [bolognese-2000-ybl1-ycl1-abstract]. The ability of these histone-fold proteins to participate in multiple complexes reflects the modular nature of chromatin-associated machinery and suggests that CHRAC1 may coordinate chromatin remodeling with DNA replication at a molecular level.

Subcellular Localization

CHRAC1 localizes to the nucleus, consistent with its function in chromatin remodeling. According to the Human Protein Atlas, the protein is specifically localized to the nucleoplasm. Based on ortholog data and functional studies, CHRAC1 is also found at pericentromeric heterochromatin regions [fyodorov-2004-acf1-chromatin-abstract]. This heterochromatic localization is functionally significant, as the ACF1-containing complexes (including CHRAC) have been implicated in heterochromatin formation and maintenance.

The targeting of CHRAC to specific chromatin regions appears to be mediated primarily through the ACF1 subunit, which contains multiple chromatin-reading domains including a PHD finger and bromodomain. ACF1 specifically targets heterochromatin through its N-terminal region, and the CHRAC1-containing complex accumulates at sites of pericentromeric heterochromatin replication during S phase.

Biological Processes and Pathways

DNA Replication

CHRAC participates in DNA replication by facilitating access of the replication machinery to chromatin-covered origins and by promoting replication through condensed chromatin regions. The pioneering study by Alexiadis and colleagues demonstrated that CHRAC could facilitate initiation of SV40 DNA replication from a nucleosomal origin by enabling T-antigen access to chromatin-covered sequences [alexiadis-1998-sv40-replication-abstract]. This finding established a direct role for chromatin remodeling in DNA replication initiation.

In Drosophila, loss of ACF1 (which disrupts both ACF and CHRAC complexes) results in accelerated progression through S phase, consistent with reduced chromatin-mediated repression of DNA replication [fyodorov-2004-acf1-chromatin-abstract]. The ACF1-SMARCA5 complex is specifically enriched in replicating pericentromeric heterochromatin, and depletion of ACF1 by RNA interference specifically impairs heterochromatin replication. These findings indicate that CHRAC1, as part of the CHRAC complex, facilitates the replication of heterochromatic regions that would otherwise present a barrier to the replication fork.

Chromatin Organization and Gene Silencing

CHRAC1 participates in establishing and maintaining organized chromatin structure. The ACF/CHRAC complexes promote the formation of repressive chromatin by generating regularly spaced nucleosome arrays from irregular chromatin [vargaweisz-1997-chrac-nature-abstract][fyodorov-2004-acf1-chromatin-abstract]. Loss of ACF1 in Drosophila results in decreased periodicity of nucleosome arrays and shorter nucleosomal repeat length in bulk chromatin, demonstrating the importance of these complexes in chromatin organization.

Genetically, ACF1 (and by extension CHRAC) contributes to transcriptional silencing in pericentromeric heterochromatin and in regions regulated by Polycomb group proteins [fyodorov-2004-acf1-chromatin-abstract]. The CHRAC/ACF complexes have been described as contributing to the "repressive ground state of chromatin," establishing an inactive baseline from which gene expression must be activated.

DNA Repair

Components of the CHRAC complex, particularly SMARCA5/SNF2H and ACF1, have been implicated in DNA repair pathways. Recent studies have elucidated the mechanism by which the ACF complex is recruited to sites of DNA damage. ADP-ribosylation signaling, which marks sites of DNA lesions, orchestrates the recruitment of various repair factors and chromatin remodeling complexes during the early stages of the DNA damage response. The ACF complex accumulates at DNA lesions in an ADP-ribosylation-dependent manner, though interestingly, each subunit (SMARCA5 and ACF1) accumulates independently from its partner. The recruitment of these proteins is not due to direct binding to ADP-ribose moieties but rather results from facilitated DNA binding at relaxed, ADP-ribosylated chromatin. ACF1 and SMARCA5 facilitate both nucleotide excision repair and transcription-coupled nucleotide excision repair (TC-NER) following UV irradiation. While the specific contribution of CHRAC1 to DNA repair has not been extensively characterized, its role in enhancing the nucleosome sliding activity of the CHRAC complex suggests participation in repair-associated chromatin remodeling that facilitates access of repair machinery to damaged DNA.

Expression Pattern

Northern blot analysis revealed that CHRAC1 is expressed ubiquitously across human tissues, producing a 2.4-kb transcript [poot-2000-huchrac-abstract]. The expression pattern of CHRAC1 parallels that of its heterodimer partner POLE3 (CHRAC-17), suggesting coordinated regulation of these functionally linked genes. According to the Human Protein Atlas, CHRAC1 shows low tissue specificity, with expression detected in virtually all major tissue types.

The highest expression levels are observed in bone marrow (26.4 nTPM), skeletal muscle (26.1 nTPM), tonsil (24.5 nTPM), and blood vessel (22.3 nTPM). In the brain, white matter shows the highest regional expression (32.2 nTPM). At the single-cell level, early primary spermatocytes show exceptionally high CHRAC1 expression (91.8 nCPM), potentially reflecting the intense chromatin remodeling activity required during meiosis. This is consistent with the recently described essential role of SMARCA5 in male meiosis and fertility.

Evolutionary Conservation

CHRAC1 is highly conserved across metazoan species, reflecting the fundamental importance of the CHRAC complex in chromatin biology. The Drosophila homolog CHRAC-16 shows significant sequence conservation with human CHRAC1, particularly within the histone-fold domain. Both proteins share the H2A-type HFD structure and the ability to heterodimerize with their POLE3/CHRAC-14 partners [corona-2000-chrac14-16-abstract].

The conservation extends beyond the histone-fold motif to include the N- and C-terminal regions, suggesting functional importance for these apparently unstructured domains [bolognese-2000-ybl1-ycl1-abstract]. The yeast ISW2 chromatin remodeling complex also contains a pair of histone-fold proteins, indicating that this organization of chromatin remodeling complexes predates the divergence of fungi and animals.

Disease Associations and Therapeutic Implications

Recent studies have revealed significant associations between CHRAC1 and cancer progression, particularly through its interaction with the Hippo pathway effector YAP. Wang and colleagues in 2022 demonstrated that CHRAC1 is highly expressed in lung cancer tissues, and this elevated expression correlates with poor prognosis in lung cancer patients [wang-2022-chrac1-lung-cancer-abstract]. Their functional studies showed that CHRAC1 overexpression promotes lung cancer cell proliferation and migration both in vitro and in vivo using a genetically engineered KrasG12D.LSL lung adenocarcinoma mouse model. Conversely, CHRAC1 silencing inhibited cell proliferation, migration, and tumor growth in xenograft models. Mechanistically, CHRAC1 binds to YAP and enhances the transcription of downstream oncogenic targets in the Hippo pathway, thereby promoting tumor growth [wang-2022-chrac1-lung-cancer-abstract].

These findings were extended by Li and colleagues in 2024, who demonstrated that CHRAC1 promotes tumor growth in breast and cervical cancer through the same YAP-mediated mechanism [li-2024-chrac1-cancer-abstract]. CHRAC1 depletion suppressed cancer cell proliferation and tumor growth, while elevated CHRAC1 expression correlated with worse patient outcomes, advanced disease stages, and metastasis. The interaction between CHRAC1 and YAP appears to be indirect and may be mediated by other components of the CHRAC complex, such as ACF1 or SMARCA5, consistent with the relatively small size of CHRAC1 (15 kDa).

Analysis of The Cancer Genome Atlas (TCGA) data has revealed that CHRAC1, along with its complex partners BAZ1A and POLE3, is simultaneously upregulated in multiple tumor types including esophageal carcinoma, liver hepatocellular carcinoma, stomach adenocarcinoma, and breast invasive carcinoma [zhou-2021-iswi-cancer-review-summary]. The CHRAC1 gene is located on chromosome 8q24.3, a region frequently amplified in cancer, and has been identified as a driver gene promoting proliferation and clonal survival of breast cancer cells.

More broadly, the ISWI chromatin remodeling complexes including CHRAC have been implicated in various cancers. SMARCA5, the catalytic subunit of CHRAC, is upregulated in acute myeloid leukemia and has been linked to breast, lung, and gastric cancers [zhou-2021-iswi-cancer-review-summary]. The emerging understanding of CHRAC1's role in cancer, particularly its function as a YAP coactivator, suggests it may represent a potential therapeutic target, though further research is needed to fully characterize its contribution to oncogenesis and determine whether its chromatin remodeling function can be specifically targeted.

Open Questions

Despite significant advances in understanding CHRAC1 function, several important questions remain:

1. Specificity of CHRAC1 versus POLE4 interactions with POLE3: Both CHRAC1 and POLE4 form heterodimers with POLE3, but the factors determining which complex assembles in different cellular contexts are not fully understood. How is the partitioning of POLE3 between chromatin remodeling and DNA replication functions regulated?

2. Direct contribution to DNA repair: While the SMARCA5-ACF1 complex is clearly implicated in DNA repair, the specific contribution of CHRAC1 to repair pathways has not been definitively established. Does CHRAC1 have distinct functions in repair versus replication-associated chromatin remodeling?

3. Tissue-specific functions: Despite ubiquitous expression, CHRAC1 may have tissue-specific roles, particularly in contexts requiring intensive chromatin remodeling such as spermatogenesis. What are the consequences of CHRAC1 deficiency in specific cell types?

4. Mechanistic details of YAP interaction: The recently discovered interaction between CHRAC1 and YAP in cancer contexts raises questions about whether this represents a normal physiological function or a pathological gain-of-function. Does CHRAC1 regulate Hippo pathway targets in normal cells?

5. Post-translational modifications: The role of post-translational modifications of CHRAC1 in regulating its function, localization, and protein interactions remains largely unexplored.

6. Relationship to other histone-fold proteins: CHRAC1 shares structural features with NF-YC and NC2alpha, which function in transcription. Whether CHRAC1 has any direct roles in transcriptional regulation beyond chromatin remodeling merits investigation.

References

• [vargaweisz-1997-chrac-nature-abstract] Varga-Weisz PD, Wilm M, Bonte E, Dumas K, Mann M, Becker PB. Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature. 1997 Aug 7;388(6642):598-602. DOI: 10.1038/41587. PMID: 9252192.

• [poot-2000-huchrac-abstract] Poot RA, Dellaire G, Hülsmann BB, Grimaldi MA, Corona DF, Becker PB, Bickmore WA, Varga-Weisz PD. HuCHRAC, a human ISWI chromatin remodelling complex contains hACF1 and two novel histone-fold proteins. EMBO J. 2000 Jul 3;19(13):3377-87. DOI: 10.1093/emboj/19.13.3377. PMID: 10880450.

• [corona-2000-chrac14-16-abstract] Corona DF, Eberharter A, Budde A, Deuring R, Ferrari S, Varga-Weisz P, Wilm M, Tamkun J, Becker PB. Two histone fold proteins, CHRAC-14 and CHRAC-16, are developmentally regulated subunits of chromatin accessibility complex (CHRAC). EMBO J. 2000 Jun 15;19(12):3049-59. DOI: 10.1093/emboj/19.12.3049. PMID: 10856248.

• [bolognese-2000-ybl1-ycl1-abstract] Bolognese F, Imbriano C, Caretti G, Mantovani R. Cloning and characterization of the histone-fold proteins YBL1 and YCL1. Nucleic Acids Res. 2000 Oct 1;28(19):3830-8. DOI: 10.1093/nar/28.19.3830. PMID: 11000277.

• [li-2000-pole3-pole4-abstract] Li Y, Pursell ZF, Linn S. Identification and cloning of two histone fold motif-containing subunits of HeLa DNA polymerase epsilon. J Biol Chem. 2000 Jul 28;275(30):23247-52. DOI: 10.1074/jbc.M002548200. PMID: 10801849.

• [langst-1999-nucleosome-movement-abstract] Längst G, Bonte EJ, Corona DF, Becker PB. Nucleosome movement by CHRAC and ISWI without disruption or trans-displacement of the histone octamer. Cell. 1999 Jun 25;97(7):843-52. DOI: 10.1016/s0092-8674(00)80797-7. PMID: 10399913.

• [alexiadis-1998-sv40-replication-abstract] Alexiadis V, Varga-Weisz PD, Bonte E, Becker PB, Gruss C. In vitro chromatin remodelling by chromatin accessibility complex (CHRAC) at the SV40 origin of DNA replication. EMBO J. 1998 Jun 15;17(12):3428-38. DOI: 10.1093/emboj/17.12.3428. PMID: 9628878.

• [kukimoto-2004-chrac15-17-sliding-abstract] Kukimoto I, Elderkin S, Grimaldi M, Oelgeschläger T, Varga-Weisz PD. The histone-fold protein complex CHRAC-15/17 enhances nucleosome sliding and assembly mediated by ACF. Mol Cell. 2004 Jan 30;13(2):265-77. DOI: 10.1016/s1097-2765(03)00523-9. PMID: 14759371.

• [fyodorov-2004-acf1-chromatin-abstract] Fyodorov DV, Blower MD, Karpen GH, Kadonaga JT. Acf1 confers unique activities to ACF/CHRAC and promotes the formation rather than disruption of chromatin in vivo. Genes Dev. 2004 Jan 15;18(2):170-83. DOI: 10.1101/gad.1139604. PMID: 14752009.

• [hartlepp-2005-structure-mechanism-abstract] Hartlepp KF, Fernández-Tornero C, Eberharter A, Grüne T, Müller CW, Becker PB. The histone fold subunits of Drosophila CHRAC facilitate nucleosome sliding through dynamic DNA interactions. Mol Cell Biol. 2005 Nov;25(22):9886-96. DOI: 10.1128/MCB.25.22.9886-9896.2005. PMID: 16260604.

• [gnesutta-2013-hfd-proteins-abstract] Gnesutta N, Nardini M, Mantovani R. The H2A/H2B-like histone-fold domain proteins at the crossroad between chromatin and different DNA metabolisms. Transcription. 2013 May 16;4(3):114-119. DOI: 10.4161/trns.25002. PMID: 23695160.

• [wang-2022-chrac1-lung-cancer-abstract] Wang M, Li S, Guo W, Wang L, Huang J, Zhuo J, Lai B, Liao C, Ge T, Nie Y, Jin S, Wang M, Zhang Y, Liu Y, Li X, Zhang H. CHRAC1 promotes human lung cancer growth through regulating YAP transcriptional activity. Carcinogenesis. 2022 Apr 25;43(3):264-276. DOI: 10.1093/carcin/bgab103. PMID: 34718437.

• [li-2024-chrac1-cancer-abstract] Li S, Wang L, Shi J, Chen Y, Xiao A, Huo B, Tian W, Zhang S, Yang G, Gong W, Zhang H. Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer. PeerJ. 2024 Jan 10;12:e16752. DOI: 10.7717/peerj.16752. PMID: 38223760.

• [zhou-2021-iswi-cancer-review-summary] Zhou M, Yuan J, Deng Y, Fan X, Shen J. The emerging role of ISWI chromatin remodeling complexes in cancer. J Exp Clin Cancer Res. 2021 Nov 12;40(1):346. DOI: 10.1186/s13046-021-02151-x. PMID: 34772431.

Citations

1. alexiadis-1998-sv40-replication-abstract.md
2. bolognese-2000-ybl1-ycl1-abstract.md
3. corona-2000-chrac14-16-abstract.md
4. fyodorov-2004-acf1-chromatin-abstract.md
5. gnesutta-2013-hfd-proteins-abstract.md
6. hartlepp-2005-structure-mechanism-abstract.md
7. kukimoto-2004-chrac15-17-sliding-abstract.md
8. langst-1999-nucleosome-movement-abstract.md
9. li-2000-pole3-pole4-abstract.md
10. li-2024-chrac1-cancer-abstract.md
11. poot-2000-huchrac-abstract.md
12. vargaweisz-1997-chrac-nature-abstract.md
13. wang-2022-chrac1-lung-cancer-abstract.md
14. zhou-2021-iswi-cancer-review-summary.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan and verification
- Identity check: The target is Homo sapiens CHRAC1 (UniProt Q9NRG0), also known as CHRAC-15/CHRAC15 and frequently referred to as POLE4 in the literature. It is a small histone-fold protein that forms a histone-fold heterodimer with CHRAC17/POLE3. This heterodimer functions within human CHRAC/ACF ISWI chromatin-remodeling complexes together with SMARCA5 (SNF2H) and BAZ1A (ACF1). This matches the UniProt description, organism, and domain annotations (histone fold/CBFA_NFYB family) (brown2010atpdependentchromatinremodeling pages 92-97, hartlepp2006characterisationofchrac14 pages 116-119).

Key concepts and definitions
- CHRAC1 (CHRAC-15/POLE4): A human histone-fold protein that heterodimerizes with CHRAC17/POLE3. As a dimer, it acts as a histone analog/chaperone module in chromatin-associated complexes, particularly ISWI remodelers (CHRAC/ACF) (brown2010atpdependentchromatinremodeling pages 92-97).
- Histone-fold heterodimer (POLE3–POLE4): A conserved H2A–H2B–like pair that associates with ISWI remodelers and with the DNA polymerase epsilon complex (orthology-based evidence), supporting nucleosome sliding/spacing and replication-coupled histone handling (brown2010atpdependentchromatinremodeling pages 92-97, hartlepp2006characterisationofchrac14 pages 116-119, casari2022resectionofdna pages 213-217).
- CHRAC/ACF complexes: ISWI-family ATP-dependent chromatin remodeling assemblies consisting of SMARCA5 (SNF2H) and BAZ1A (ACF1); in CHRAC, the POLE3–POLE4 heterodimer (CHRAC17–CHRAC15) enhances ATP-dependent nucleosome sliding activity and contributes to nucleosome spacing (brown2010atpdependentchromatinremodeling pages 92-97, borner2017rolesofnucleosome pages 22-25, jain2015effectsofnucleosome pages 95-99).
- Domain context: CHRAC1 contains a histone-fold/CBFA_NFYB-like domain; partner BAZ1A contributes WAC/DDT and PHD/bromodomain modules for chromatin targeting, and the histone-fold heterodimer engages the ACF1 N-terminus (WAC motif) (hartlepp2006characterisationofchrac14 pages 116-119, borner2017rolesofnucleosome pages 22-25).

Recent developments and latest research (priority 2022–2024)
- 2024 human ISWI interactome context: Tissue-specific interaction partners of SMARCA5 emphasize that CHRAC/ACF are major ISWI complexes mediating nucleosome spacing, with BAZ1A guiding targeting and SMARCA5 providing ATPase activity; the complex is implicated in DNA repair contexts (no CHRAC1-specific proteomics, but directly relevant complex-level updates) (Arishaka 2024; publication type: study/dissertation; URL not available) (arishaka2024identificationofnew pages 17-21).
- 2022 Drosophila mechanistic links with centromere and stress: The histone-fold subunit CHRAC-14 (fly ortholog of human POLE3/POLE4 family) regulates CENP-A loading and gene expression, shows context-dependent associations with centromeric proteins and other remodelers under DNA damage, and interacts with Pol ε–related factors (Mes4), underscoring a conserved theme of CHRAC histone-fold dimers in centromere function and stress-responsive chromatin maintenance (Doppler 2022; https://doi.org/10.11588/heidok.00031436; Jan 2022) (doppler2022thehistonefold pages 20-23, doppler2022thehistonefold pages 73-75).
- 2022 synthesis on DSB resection and replication chaperoning: Review synthesizes that POLE3–POLE4 (Dbp3/Dbp4 orthologs) serve in replication-coupled histone handling and that ISWI remodelers contribute to DSB processing, situating CHRAC1’s histone-fold dimer within DNA replication and repair pathways (Casari 2022; review; URL not available) (casari2022resectionofdna pages 213-217).

Molecular function and biochemical roles
- Structural role: CHRAC1 functions as a histone-fold protein forming a stable heterodimer with CHRAC17/POLE3 that mimics H2A–H2B. This dimer enhances ISWI remodeling activities, particularly nucleosome sliding by SMARCA5–BAZ1A, and contributes to nucleosome spacing/assembly (brown2010atpdependentchromatinremodeling pages 92-97, borner2017rolesofnucleosome pages 22-25, jain2015effectsofnucleosome pages 95-99).
- Interaction with remodelers: The heterodimer engages ACF1’s N-terminus (WAC motif), supporting assembly and function of ACF/CHRAC complexes (hartlepp2006characterisationofchrac14 pages 116-119).
- Replication-associated chaperone function: Orthology-informed and review-based evidence indicates that the POLE3–POLE4 pair acts as a histone chaperone at replication forks for parental histone (H3–H4) redeposition; Drosophila and yeast lines of evidence place the histone-fold pair at the replication-coupled chromatin interface (casari2022resectionofdna pages 213-217, borner2017rolesofnucleosome pages 22-25).

Subcellular localization
- Nuclear: The CHRAC15/CHRAC17 (POLE4/POLE3) histone-fold dimer is imported to the nucleus as a heterodimer; ACF1/SNF2H accumulate at pericentric heterochromatin in late S-phase in referenced cell studies, consistent with nuclear chromatin roles (Brown 2010) (brown2010atpdependentchromatinremodeling pages 92-97).

Biological processes and pathways
- Chromatin remodeling and organization: CHRAC/ACF remodelers slide and space nucleosomes to promote chromatin assembly and establish a repressive ground state of chromatin; the CHRAC1-containing histone-fold dimer enhances these activities (borner2017rolesofnucleosome pages 22-25, jain2015effectsofnucleosome pages 95-99).
- DNA replication: The POLE3–POLE4 histone-fold chaperone pair supports replication-coupled parental histone handling and chromatin integrity; in human cells, CHRAC1 (POLE4) is the CHRAC component of this conserved module (casari2022resectionofdna pages 213-217, brown2010atpdependentchromatinremodeling pages 92-97).
- DNA damage response and repair: Evidence from Drosophila shows CHRAC histone-fold subunits contribute to DNA damage checkpoint integrity and repair efficiency; broader reviews link ISWI remodelers to DSB resection and processing, situating CHRAC1 at the interface of chromatin remodeling and repair (doppler2022thehistonefold pages 20-23, casari2022resectionofdna pages 213-217).
- Centromere/kinetochore regulation: Drosophila data indicate CHRAC-14 limits aberrant CENP-A loading and engages centromeric interactors; this suggests conserved centromeric chromatin maintenance roles for the histone-fold dimer family (doppler2022thehistonefold pages 20-23, doppler2022thehistonefold pages 73-75).

Current applications and real-world implementations
- Functional genomics and proteomics: Co-immunoprecipitation/mass spectrometry approaches identify CHRAC/ACF complex constituents and replication-linked associates (e.g., RFC subunits, Cdc6) in vivo, informing network models of replication-coupled chromatin maintenance where CHRAC1 participates (Jain 2015; https://doi.org/10.5282/edoc.19018; Jan 2015) (jain2015effectsofnucleosome pages 95-99).
- Chromatin and replication stress models: Cellular studies tracking ISWI/ACF1 localization during S phase and heterochromatin replication, and fly models of DNA damage/centromere regulation, are used to infer conserved roles of human CHRAC1 in chromatin robustness under replication stress (brown2010atpdependentchromatinremodeling pages 92-97, doppler2022thehistonefold pages 20-23).

Expert opinions and authoritative synthesis
- Mechanistic reviews emphasize that ISWI remodelers (including CHRAC/ACF) function in nucleosome spacing and repressive chromatin, and that POLE3–POLE4 serves a replication-coupled histone chaperone role; these syntheses provide consensus for CHRAC1’s placement in chromatin remodeling–replication interfaces (casari2022resectionofdna pages 213-217, borner2017rolesofnucleosome pages 22-25).

Relevant statistics and data points
- Nuclear import: CHRAC15–CHRAC17 imported as a heterodimer; ACF1/SNF2H colocalization at pericentric heterochromatin in late S phase (cell-based observations summarized in Brown 2010) (brown2010atpdependentchromatinremodeling pages 92-97).
- DNA damage phenotypes (fly): Depletion of CHRAC-14 causes hypersensitivity to genotoxic stress, failure of G2/M checkpoint, accumulation of γH2Av, and comet assay DNA damage, suggesting a conserved role in the DNA damage response; while quantitative values are not provided in the excerpt, the directionality is consistent and supported (Doppler 2022; Jan 2022) (doppler2022thehistonefold pages 20-23).

Open questions and limitations
- Direct, recent (2023–2024) human CHRAC1-specific mechanistic papers are limited in the present evidence set. Current understanding extrapolates from conserved complex biology, Drosophila/yeast orthologs, and reviews. Targeted human CHRAC1 studies defining its unique contributions beyond the POLE3–POLE4 dimer function remain an active area.

Source summary with URLs and dates
- Brown 2010. Atp-dependent chromatin remodeling complexes in Xenopus development. Summary includes human CHRAC composition and nuclear import; URL not available in excerpt (brown2010atpdependentchromatinremodeling pages 92-97).
- Doppler 2022. The histone fold protein CHRAC-14 controls CENP-A loading and gene expression in Drosophila melanogaster. Jan 2022. https://doi.org/10.11588/heidok.00031436 (doppler2022thehistonefold pages 20-23, doppler2022thehistonefold pages 73-75).
- Hartlepp 2006. Characterisation of CHRAC14 and CHRAC16… Jan 2006. https://doi.org/10.5282/edoc.5149 (hartlepp2006characterisationofchrac14 pages 116-119).
- Börner 2017. Roles of nucleosome remodeling factors ACF1 and Domino during Drosophila melanogaster oogenesis. Jan 2017. https://doi.org/10.5282/edoc.20348 (borner2017rolesofnucleosome pages 22-25).
- Jain 2015. Effects of nucleosome remodeling factor ACF1 on in vivo chromatin organization. Jan 2015. https://doi.org/10.5282/edoc.19018 (jain2015effectsofnucleosome pages 95-99).
- Casari 2022. Resection of DNA double-strand breaks: novel regulatory mechanisms by checkpoint proteins and chromatin remodelers. 2022. URL not available in excerpt (casari2022resectionofdna pages 213-217).
- Arishaka 2024. Identification of new tissue-specific interaction partners of chromatin remodelling ATPase Smarca5. 2024. URL not available in excerpt (arishaka2024identificationofnew pages 17-21).

Embedded evidence table
| Reference (first author, year) | Focus / Model | What it shows about CHRAC1/POLE4 or CHRAC complexes (one-sentence) | Key partners / complexes mentioned | URL (DOI or link) | Publication date (month/year) |
|---|---|---|---|---:|---:|
| Brown 2010 (brown2010atpdependentchromatinremodeling pages 92-97) | Review / Xenopus / comparative (human context discussed) | Describes CHRAC15/POLE4 as a histone-fold subunit of human HuCHRAC that forms a heterodimer with CHRAC17/POLE3, enhancing ISWI (ACF/SNF2H) nucleosome-sliding activity and imported to the nucleus as a dimer. | SNF2H (SMARCA5), ACF1 (BAZ1A), CHRAC17 (POLE3) | N/A | 2010 |
| Doppler 2022 (doppler2022thehistonefold pages 20-23) | Experimental thesis / Drosophila | Shows histone-fold CHRAC subunits (CHRAC-14) heterodimerize (with CHRAC-16), control CENP-A loading, influence gene expression, and connect to Pol ε-related factors under stress. | CHRAC-16, Mes4 (Pol ε link), CENP-A, ATRX, pBAF | https://doi.org/10.11588/heidok.00031436 | Jan/2022 |
| Doppler 2022 (doppler2022thehistonefold pages 73-75) | Experimental thesis / Drosophila (additional data) | Provides mass-spec evidence of context-dependent associations of CHRAC histone-fold subunits with centromeric proteins and other remodelers, and notes detection/antibody challenges. | CENP-A, DEK, XNP/ATRX, pBAF | https://doi.org/10.11588/heidok.00031436 | Jan/2022 |
| Arishaka 2024 (arishaka2024identificationofnew pages 17-21) | Proteomics / human tissues (SMARCA5 interactome) | Identifies tissue-specific interaction partners of SMARCA5 and emphasizes ISWI complexes (including CHRAC/ACF) in nucleosome spacing, chromatin targeting and DNA repair. | SMARCA5 (ISWI), BAZ1A (ACF1), other ISWI partners | N/A | 2024 |
| Casari 2022 (casari2022resectionofdna pages 213-217) | Review / mechanistic (multi-organism synthesis) | Summarizes conservation of CHRAC-family histone-fold subunits and links POLE3–POLE4 (Dbp3/Dbp4 orthologs) to roles in replication-coupled histone handling and DSB processing via remodeler interplay. | POLE3, POLE4, ISWI family remodelers | N/A | 2022 |
| Hartlepp 2006 (hartlepp2006characterisationofchrac14 pages 116-119) | Dissertation / molecular characterization (Drosophila focus) | Characterises CHRAC histone-fold subunits, reports structural/functional similarity between CHRAC and Pol ε histone-fold dimers, and shows interaction with ACF1 N-terminal WAC motif. | ACF1 (WAC motif), CHRAC16, Pol ε (shared subunit context) | https://doi.org/10.5282/edoc.5149 | Jan/2006 |
| Börner 2017 (borner2017rolesofnucleosome pages 22-25) | Dissertation / Drosophila oogenesis | Demonstrates ACF/CHRAC (ISWI complexes) use small histone-fold proteins as DNA chaperones for nucleosome sliding/spacing and parental histone redeposition, implicating roles at replication and chromatin assembly. | ACF1, ISWI, NAP-1 (cooperation in assembly) | https://doi.org/10.5282/edoc.20348 | Jan/2017 |
| Jain 2015 (jain2015effectsofnucleosome pages 95-99) | Proteomics / Drosophila in vivo studies | Proteomics shows stable ACF1 association with small CHRAC subunits and recovery of replication-associated proteins (RFCs, Cdc6), supporting functional links between CHRAC/ACF and replication-linked chromatin organization. | ACF1, ISWI, RFC3/RFC4, Cdc6 | https://doi.org/10.5282/edoc.19018 | Jan/2015 |

Table: Concise, sourced summary of key experimental and review evidence (2006–2024) describing CHRAC1/CHRAC‑15 (POLE4) identity, conserved histone‑fold heterodimerization, complex memberships, and roles in nucleosome sliding, replication‑linked histone handling and DNA repair (context IDs cited).

Conclusions
- CHRAC1 is the human histone-fold protein CHRAC-15/POLE4 that dimerizes with CHRAC17/POLE3, integrates into CHRAC/ACF ISWI chromatin remodeling complexes with SMARCA5 and BAZ1A, and localizes to the nucleus. This histone-fold dimer enhances nucleosome sliding/spacing, supports replication-coupled parental histone redeposition, and participates in chromatin maintenance under DNA damage and at centromeric chromatin. Current 2022–2024 sources reinforce these roles at the complex level and via orthology, while direct 2023–2024 human CHRAC1-specific mechanistic insights remain comparatively scarce and warrant further targeted investigation (brown2010atpdependentchromatinremodeling pages 92-97, doppler2022thehistonefold pages 20-23, hartlepp2006characterisationofchrac14 pages 116-119, borner2017rolesofnucleosome pages 22-25, jain2015effectsofnucleosome pages 95-99, casari2022resectionofdna pages 213-217, arishaka2024identificationofnew pages 17-21).

References

1. (brown2010atpdependentchromatinremodeling pages 92-97): EE Brown. Atp-dependent chromatin remodeling complexes in xenopus development. Unknown journal, 2010.

2. (hartlepp2006characterisationofchrac14 pages 116-119): Klaus F. Hartlepp. Characterisation of chrac14 and chrac16, the two histone fold subunits of the chromatin accessibility complex. Dissertation, Jan 2006. URL: https://doi.org/10.5282/edoc.5149, doi:10.5282/edoc.5149. This article has 0 citations.

3. (casari2022resectionofdna pages 213-217): E Casari. Resection of dna double-strand breaks: novel regulatory mechanisms by checkpoint proteins and chromatin remodelers. Unknown journal, 2022.

4. (borner2017rolesofnucleosome pages 22-25): Kenneth Börner. Roles of nucleosome remodeling factors acf1 and domino during drosophila melanogaster oogenesis. Dissertation, Jan 2017. URL: https://doi.org/10.5282/edoc.20348, doi:10.5282/edoc.20348. This article has 0 citations.

5. (jain2015effectsofnucleosome pages 95-99): Dhawal Jain. Effects of nucleosome remodeling factor acf1 on in vivo chromatin organization. Dissertation, Jan 2015. URL: https://doi.org/10.5282/edoc.19018, doi:10.5282/edoc.19018. This article has 1 citations.

6. (arishaka2024identificationofnew pages 17-21): Y Arishaka. Identification of new tissue-specific interaction partners of chromatin remodelling atpase smarca5. Unknown journal, 2024.

7. (doppler2022thehistonefold pages 20-23): Sarah Doppler. The histone fold protein chrac-14 controls cenp-a loading and gene expression in drosophila melanogaster. Text, Jan 2022. URL: https://doi.org/10.11588/heidok.00031436, doi:10.11588/heidok.00031436. This article has 0 citations and is from a peer-reviewed journal.

8. (doppler2022thehistonefold pages 73-75): Sarah Doppler. The histone fold protein chrac-14 controls cenp-a loading and gene expression in drosophila melanogaster. Text, Jan 2022. URL: https://doi.org/10.11588/heidok.00031436, doi:10.11588/heidok.00031436. This article has 0 citations and is from a peer-reviewed journal.

Citations

1. brown2010atpdependentchromatinremodeling pages 92-97
2. arishaka2024identificationofnew pages 17-21
3. casari2022resectionofdna pages 213-217
4. jain2015effectsofnucleosome pages 95-99
5. doppler2022thehistonefold pages 20-23
6. borner2017rolesofnucleosome pages 22-25
7. doppler2022thehistonefold pages 73-75
8. https://doi.org/10.11588/heidok.00031436;
9. https://doi.org/10.5282/edoc.19018;
10. https://doi.org/10.11588/heidok.00031436
11. https://doi.org/10.5282/edoc.5149
12. https://doi.org/10.5282/edoc.20348
13. https://doi.org/10.5282/edoc.19018
14. https://doi.org/10.5282/edoc.5149,
15. https://doi.org/10.5282/edoc.20348,
16. https://doi.org/10.5282/edoc.19018,
17. https://doi.org/10.11588/heidok.00031436,

CHRAC1 (Q9NRG0) – Chromatin Accessibility Complex Subunit 1 in Human

Overview and Key Concepts

CHRAC1 (Chromatin Accessibility Complex subunit 1, also known as CHRAC15 or YCL1) is a small (~15 kDa, 131 amino acids) protein that plays a structural role in chromatin remodeling and DNA replication. It was first identified as part of the CHRomatin Accessibility Complex (CHRAC), an ATP-dependent chromatin-remodeling complex originally discovered in Drosophila and later in mammals (jeccr.biomedcentral.com). CHRAC1 contains a histone-fold motif, a structural domain through which it heterodimerizes with another histone-fold protein, typically POLE3 (also called CHRAC17) (thebiogrid.org) (jeccr.biomedcentral.com). This CHRAC1–POLE3 pair is analogous to histone H2A–H2B dimers in structure (pmc.ncbi.nlm.nih.gov) and is a non-enzymatic accessory module within larger complexes. The CHRAC1/POLE3 heterodimer does not itself catalyze reactions, but it binds DNA and histones and is essential for the activity of the complexes it belongs to (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

CHRAC1 is encoded on chromosome 8 (8q24.3) and is expressed in the nucleus in most human cells. It is predicted to be intracellular and indeed localizes to the nucleoplasm (chromatin-rich nuclear space) (www.proteinatlas.org). Consistent with a fundamental role in genome maintenance, CHRAC1 shows low tissue specificity, meaning it is expressed across a wide range of cell types (www.proteinatlas.org). In summary, CHRAC1 is a conserved chromatin-associated protein that serves as a structural subunit in critical nuclear complexes for DNA packaging and replication.

Molecular Function and Structure

Histone-Fold Protein and Heterodimer Formation: CHRAC1 belongs to a family of small histone-fold proteins that function in pairs. It forms a tight heterodimer with POLE3 (also known as CHRAC17), another histone-fold protein (thebiogrid.org) (jeccr.biomedcentral.com). This dimer resembles the histone H2A–H2B dimer in both structure and DNA-binding mode (pmc.ncbi.nlm.nih.gov). Structural modeling and alignments have shown that the Drosophila CHRAC-14/16 heterodimer (homologous to human CHRAC1/POLE3) superimposes onto an H2A–H2B dimer bound to DNA (pmc.ncbi.nlm.nih.gov), highlighting the evolutionary repurposing of histone-like modules in chromatin machinery. The CHRAC1–POLE3 dimer has a positively charged surface that can bind directly to double-stranded DNA (pmc.ncbi.nlm.nih.gov). This DNA-binding ability is unique among subunits of replicative polymerases and remodelers – in fact, inclusion of the histone-fold pair allows the holoenzymes containing CHRAC1 to grip nucleic acids more stably (pmc.ncbi.nlm.nih.gov). Both yeast and human studies have demonstrated that these subunits also associate with core histones: for example, the yeast homolog (Dpb4) can be chemically crosslinked to histone proteins on DNA (pmc.ncbi.nlm.nih.gov). This suggests the heterodimer can bridge DNA and nucleosomes, stabilizing protein–DNA interactions during chromatin remodeling and replication.

Association with Complexes: CHRAC1’s primary function is as a non-catalytic subunit of larger chromatin-associated complexes. It is a dedicated component of the CHRAC/ACF family of ISWI-type chromatin remodelers. In humans, the canonical ACF (ATP-utilizing Chromatin Assembly and Remodeling Factor) complex consists of the SNF2H ATPase (SMARCA5) and the large accessory subunit ACF1 (BAZ1A) (jeccr.biomedcentral.com). When CHRAC1 and POLE3 are incorporated, this forms the four-subunit CHRAC complex (consisting of SMARCA5, BAZ1A, CHRAC1, and POLE3) (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). CHRAC1 directly interacts with ACF1 (BAZ1A) via its histone-fold partner, and this interaction is essential for the remodeler’s function (thebiogrid.org). Notably, CHRAC1 is historically referred to as “p15”, and POLE3 as “p17,” reflecting their molecular weights (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These two subunits form a stable sub-complex that can attach to different machines: they are part of CHRAC, and intriguingly, one of them (POLE3/p17) is also a subunit of the DNA polymerase ε complex (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Polymerase ε (Pol ε), the leading-strand DNA polymerase in replication, has four subunits; two are large enzymatic subunits, and two are small histone-fold subunits (POLE3 and POLE4, historically p17 and p12) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Importantly, the p17/CHRAC17 subunit is shared between Pol ε and CHRAC in mammals (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), whereas CHRAC1 (p15) is unique to the chromatin remodeling complex. This shared subunit reflects a conserved theme: in yeast, the Pol ε accessory subunit Dpb4 is also part of an ISWI remodeling complex (yeast Isw2 complex) (jeccr.biomedcentral.com). The presence of common subunits suggests functional coupling between replication and chromatin remodeling machineries.

Biochemical Activity: Although CHRAC1 itself has no enzymatic activity (it does not hydrolyze ATP or modify substrates), it is critical for the activity of its host complexes. In the context of ACF/CHRAC, CHRAC1–POLE3 acts as a modulatory module that enhances nucleosome remodeling. A key study in Molecular Cell (2004) demonstrated that adding the CHRAC1/POLE3 (p15/p17) pair to the ACF complex greatly facilitates nucleosome sliding and assembly on DNA (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). In this study, the reconstituted human CHRAC complex showed more efficient ATP-dependent repositioning of nucleosomes than the two-subunit ACF core alone, indicating that CHRAC1 and its partner improve the remodeler’s ability to mobilize histone octamers (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). The CHRAC1–POLE3 heterodimer is thought to nucleate contacts with the nucleosomal DNA or histones, aiding the SNF2H motor in gripping and moving nucleosomes (thebiogrid.org) (jeccr.biomedcentral.com). Direct interaction of the CHRAC1/POLE3 module with the ACF1 subunit is required for this stimulatory effect (thebiogrid.org), suggesting CHRAC1 acts as an adapter linking the ATPase complex to the nucleosome substrate.

Within the Pol ε holoenzyme, the analogous histone-fold pair (POLE3–POLE4) performs a different but related role. It has been shown to function as a histone chaperone – specifically binding histones H3–H4 and facilitating their proper assembly behind the replication fork (pubmed.ncbi.nlm.nih.gov). In a 2018 biochemical study, the POLE3/POLE4 subcomplex of Pol ε was found to selectively bind H3–H4 and promote replication-coupled nucleosome assembly, thereby maintaining chromatin integrity during DNA synthesis (pubmed.ncbi.nlm.nih.gov). By analogy, the CHRAC1–POLE3 dimer (which shares the POLE3 component) likely has a similar affinity for histones or DNA. In Pol ε, these small subunits also confer high affinity for double-stranded DNA, making Pol ε unique among DNA polymerases in its ability to stay attached to dsDNA without external clamps (pmc.ncbi.nlm.nih.gov). This property is crucial for holding and organizing DNA as the polymerase synthesizes the new strand. While CHRAC1 is not part of Pol ε, the shared architecture implies that CHRAC1’s presence in the CHRAC complex equips the chromatin remodeler with a DNA/histone-binding module analogous to Pol ε’s, reinforcing the idea that CHRAC1’s primary function is structural tethering: it helps position and stabilize the larger enzymatic subunits on chromatin substrates.

Biological Processes and Pathways

Chromatin Remodeling and Nucleosome Positioning: The defining role of CHRAC1 is in chromatin remodeling. CHRAC1-containing complexes (ACF/CHRAC) use the energy of ATP (via the ISWI ATPase SNF2H) to reposition nucleosomes along DNA. CHRAC was originally purified (in Drosophila) by its ability to increase chromatin accessibility – chromatin reconstituted with CHRAC was more easily cut by restriction enzymes (pmc.ncbi.nlm.nih.gov). This activity reflects the complex’s ability to slide nucleosomes and expose DNA regions. In addition, CHRAC can drive the formation of regularly spaced nucleosome arrays in vitro, organizing chromatin structure (pmc.ncbi.nlm.nih.gov). In general, ACF and CHRAC function as nucleosome spacing factors, converting irregular nucleosome distributions into evenly spaced, higher-order chromatin – a process often associated with repressive chromatin formation (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). CHRAC1 is an essential part of this process: when CHRAC1/POLE3 are bound to ACF, the complex is optimized for sliding nucleosomes along DNA and assembling histones onto DNA in an orderly manner (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). This is corroborated by experiments showing that removing or mutating the CHRAC1–POLE3 subunits impairs ATP-dependent nucleosome mobilization by ACF (jeccr.biomedcentral.com). Thus, CHRAC1’s broader structural role is to ensure chromatin remodelers can effectively reposition nucleosomes, which impacts DNA accessibility for transcription, replication, and repair.

Because of this role, CHRAC1 influences transcriptional regulation indirectly. By helping position nucleosomes, CHRAC1-containing complexes can either repress or activate gene expression depending on context. For instance, well-spaced nucleosome arrays formed by ACF/CHRAC are often linked to transcriptional repression (stabilizing a more condensed chromatin state) (jeccr.biomedcentral.com). However, chromatin remodelers can also enable transcription by clearing or sliding nucleosomes at promoters. A recent study provides a concrete example: CHRAC1 was found to interact with the transcriptional co-activator YAP (Yes-associated protein) and promote YAP-driven gene expression in cancer cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In this 2024 study (PeerJ, Jan 10 2024), Li et al. showed that CHRAC1 physically associates with YAP and is required for efficient transcription of YAP target oncogenes in breast and cervical cancer cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). CHRAC1 depletion led to reduced YAP target gene expression, suggesting that CHRAC1’s chromatin-remodeling function may facilitate opening of chromatin at YAP-regulated loci to enhance transcription (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This illustrates how CHRAC1, through the CHRAC complex, can participate in specific gene regulatory programs – not by sequence-specific DNA binding, but by modulating nucleosome positioning at the behest of other DNA-binding factors.

DNA Replication and Epigenetic Maintenance: CHRAC1 is also important in the context of DNA replication. While it is not a core component of the replication fork machinery, its relationships to Pol ε and chromatin assembly tie it closely to replication processes. The leading-strand DNA polymerase ε, which synthesizes new DNA during S-phase, contains a histone-fold subcomplex (POLE3–POLE4) related to CHRAC1–POLE3. This subcomplex chaperones histones and helps re-deposit them onto newly replicated DNA (pubmed.ncbi.nlm.nih.gov). Because POLE3 is common to both Pol ε and CHRAC, there appears to be a division of labor: Pol ε (with POLE3–POLE4) handles immediate nucleosome reassembly, while CHRAC (with CHRAC1–POLE3) may assist in specialized contexts of replication, such as heterochromatin. Indeed, evidence suggests CHRAC is recruited during replication of heterochromatic regions to ensure proper chromatin is reformed. Two core components of CHRAC (SNF2H and ACF1) have been observed to colocalize with heterochromatin protein HP1β and with BrdU (newly synthesized DNA) during late S phase (pmc.ncbi.nlm.nih.gov). Late S-phase is when pericentromeric heterochromatin is replicated, and this colocalization indicates CHRAC is present at replication sites of silent repetitive DNA. Researchers propose that the shared POLE3/p17 subunit might serve as a molecular link, targeting both Pol ε and CHRAC to replicating heterochromatic regions (pmc.ncbi.nlm.nih.gov). In this model, Pol ε synthesizes DNA while CHRAC remodels nucleosomes in tandem, thereby maintaining the epigenetic state (silenced or open) of the DNA after replication (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Experimental support comes from yeast: disruption of Dpb4 (the yeast POLE3 homolog shared with yeast CHRAC) causes defects in inheriting silent chromatin at telomeres, showing equal parts loss and gain of silencing (pmc.ncbi.nlm.nih.gov). Similarly, in human cells, Pol ε and CHRAC cooperate to replicate through dense chromatin – Pol ε’s small subunits and CHRAC can both bind histones/DNA, helping to propagate chromatin structure onto daughter strands (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Moreover, cell-free replication assays have demonstrated a direct role for CHRAC in assisting DNA synthesis through chromatin: for example, adding purified human CHRAC to an in vitro replication system allowed more efficient duplication of nucleosomal DNA by repositioning nucleosomes at a replication origin that would otherwise block replication initiation (pmc.ncbi.nlm.nih.gov). This indicates CHRAC1’s complex actively helps overcome nucleosomal barriers during replication, ensuring that DNA replication progresses and that nucleosomes are properly reassembled afterward.

DNA Repair and Other Pathways: There is also evidence implicating CHRAC1-containing complexes in DNA damage responses. The ACF1–SNF2H remodeler (with which CHRAC1 associates in CHRAC) is known to be recruited to DNA double-strand breaks and contribute to repair. BAZ1A (ACF1) and SNF2H help load repair factors at breaks and promote non-homologous end joining, and loss of either makes cells hypersensitive to DNA damage (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). CHRAC1 has not been singled out in these studies, but as part of the same complex it likely participates in chromatin relaxation around DNA breaks, facilitating repair factor access. Additionally, CHRAC1’s partner POLE3 has been linked to stabilizing replication forks under stress – recent work showed that loss of POLE3/POLE4 leads to replication gaps and hypersensitivity to PARP inhibitors (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). While these studies focused on Pol ε’s subunits, they underscore the importance of the histone-fold modules in maintaining genome stability. By extension, CHRAC1 (through CHRAC) contributes to safeguarding genome integrity during both routine DNA duplication and in response to genotoxic stress.

In summary, CHRAC1 functions at the crossroads of several fundamental pathways: it is a key adapter in ATP-dependent chromatin remodeling, it supports DNA replication-coupled chromatin assembly, and it likely plays auxiliary roles in transcription regulation and DNA repair by modulating nucleosome behavior. All these roles center on managing nucleosome positioning and stability, highlighting CHRAC1’s primary role as a structural keeper of chromatin states.

Cellular Localization

CHRAC1 is an intracellular, nuclear protein. It lacks any signal peptides or transmembrane domains, and consistent with its role in chromatin dynamics, it localizes to the cell nucleus, predominantly in the nucleoplasm (the chromatin-containing portion of the nucleus) (www.proteinatlas.org). High-resolution microscopy and cell fractionation experiments support this: CHRAC1 is found in the chromatin-bound fraction of nuclear extracts and co-localizes with known chromatin markers. For instance, as noted, components of the CHRAC complex including SNF2H and ACF1 (which would carry CHRAC1 with them) concentrate at pericentromeric heterochromatin foci marked by HP1 during S phase (pmc.ncbi.nlm.nih.gov). Additionally, Pol ε (which shares the POLE3 subunit) localizes to replication foci that overlap with sites of DNA synthesis (PCNA/BrdU foci) in S phase (pmc.ncbi.nlm.nih.gov), and by proxy CHRAC may be present in those same foci to assist nucleosome assembly. Immunofluorescence studies in cancer cells also show CHRAC1 nuclear localization. In a recent study, CHRAC1 and YAP were observed to interact in the nucleus; CHRAC1 showed punctate nuclear staining and co-localized with YAP in transcriptionally active nuclear regions (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). No evidence exists for CHRAC1 functioning outside the nucleus—it is fundamentally tied to chromatin, which is a nuclear entity. Therefore, CHRAC1 carries out its function in the nuclear chromatin context, at sites where DNA is being read, copied, or repaired.

Recent Developments and Clinical Significance

Emerging research, particularly in the last few years, has highlighted CHRAC1’s relevance in disease (notably cancer) and its potential as a therapeutic target. The CHRAC1 gene is located at 8q24.3, a chromosomal region frequently amplified in cancers. A 2014 oncogenomic study (Mahmood et al., Carcinogenesis 2014) identified CHRAC1 as a driver gene within the 8q24.3 amplicon in breast cancer (jeccr.biomedcentral.com). In that RNA interference screen, CHRAC1 was one of a handful of genes whose knockdown impaired the proliferation and survival of breast cancer cells harboring the 8q24 amplification (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). This indicates that overexpression of CHRAC1 can confer a growth advantage to tumor cells. Expanding on this, a pan-cancer analysis (2021) found that CHRAC1 and its complex members are frequently upregulated or amplified in multiple tumor types. Transcriptomic data from The Cancer Genome Atlas (TCGA) show concurrent overexpression of BAZ1A (ACF1), CHRAC1, and POLE3 in diverse cancers including esophageal carcinoma, hepatocellular carcinoma, gastric cancer, and breast carcinoma (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). In many tumors, at least two subunits of the CHRAC complex are aberrantly co-amplified or overexpressed, suggesting selective pressure to boost CHRAC activity in cancer cells (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). This makes sense in light of CHRAC1’s function: increased chromatin remodeling capacity might enable cancer cells to more easily reprogram gene expression or tolerate replication stress. For example, CHRAC1 was found to be upregulated in cisplatin-resistant ovarian cancer cell lines and in metastatic lung tumors, with CHRAC1 knockdown reducing migration and invasion of those cancer cells (pmc.ncbi.nlm.nih.gov). These observations imply CHRAC1 contributes to therapy resistance and aggressive phenotypes, possibly by altering chromatin to activate survival pathways.

One of the most striking recent findings is CHRAC1’s connection to the Hippo signaling pathway via YAP. As mentioned, PeerJ (2024) reported that CHRAC1 physically interacts with YAP and enhances the transcription of YAP target genes, which include many pro-proliferative and anti-apoptotic factors (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Functionally, silencing CHRAC1 in breast and cervical cancer models suppressed tumor cell proliferation and tumor growth in vivo, correlating with reduced expression of YAP-driven oncogenes (pmc.ncbi.nlm.nih.gov). Clinically, CHRAC1 protein levels were found to be elevated in patient tumor samples (breast and cervical cancers), and high CHRAC1 expression was associated with poorer patient survival, higher tumor grade, and increased metastasis (pmc.ncbi.nlm.nih.gov). This positions CHRAC1 as not only a biomarker of aggressive disease but also a potential therapeutic target. If CHRAC1 is required for the oncogenic gene expression program (like YAP’s program), drugs that inhibit the CHRAC complex or disrupt CHRAC1–YAP interaction might curb tumor growth. Indeed, interest in targeting chromatin remodelers in cancer is growing, and CHRAC1 lies at the intersection of chromatin regulation and oncogenic signaling.

Beyond cancer, CHRAC1’s role in fundamental processes means that any dysregulation could have wide effects. As a coregulator of chromatin structure, CHRAC1 might be involved in disorders of genome instability or developmental epigenetic diseases, though these have not been well characterized yet. It’s worth noting that knocking out the mouse homolog of CHRAC1 has not been widely reported in literature – given its role, a complete CHRAC1 knockout might be embryonic lethal or cause severe proliferation defects, which would align with it being a housekeeping gene. Consortium databases do indicate CHRAC1 is essential for cell viability in various cell lines (for instance, CRISPR screens list CHRAC1 among genes needed for growth in culture (jeccr.biomedcentral.com) (jeccr.biomedcentral.com)), reinforcing that it is not easily dispensable.

Expert Commentary and Concluding Remarks

CHRAC1 exemplifies how small structural proteins can have outsized importance in genome regulation. As part of the ISWI-family chromatin remodelers, it alters the physical arrangement of nucleosomes, which is a fundamental mechanism for controlling access to DNA (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). Experts note that the sharing of a subunit between a chromatin remodeler and a DNA polymerase is a remarkable evolutionary solution to couple nucleosome dynamics with DNA replication (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Dr. Zachary Pursell and Dr. Thomas Kunkel, in their comprehensive 2008 review of DNA Pol ε, highlighted the mystery of “why two entirely separate enzymatic activities should have such a shared subunit” (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). One hypothesis they offer is that the shared histone-fold subunit (POLE3/CHRAC17) could serve as a bridge between replication and chromatin assembly, ensuring that as the replication fork progresses, the chromatin structure is re-established immediately and correctly (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). CHRAC1, partnering in the CHRAC complex, appears to complement this by providing the chromatin remodeling horsepower needed especially in tightly packed regions.

Chromatin biology experts like Dr. Philippe Clapier have also underscored the importance of histone-fold proteins in chromatin transactions. In a 2017 review, Clapier et al. noted that histone-fold subunits (like CHRAC1 and its partners) not only serve as structural components but can act as “accessory DNA-binding modules” that increase the efficiency and targeting of remodeling enzymes (pmc.ncbi.nlm.nih.gov). The case of CHRAC1 validates this: without directly binding specific DNA sequences or catalyzing reactions, it nonetheless directs where and how the energy of SNF2H is applied on nucleosomes.

From a clinical perspective, cancer researchers (e.g. in the 2021 JECCR review) point out that ISWI complexes such as CHRAC are emerging as critical drivers in oncogenesis when deregulated (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). The simultaneous up-regulation of CHRAC1 and its complex members in tumors suggests a selective advantage, possibly allowing cancer cells to rapidly restructure their chromatin for tumor-promoting gene expression programs (jeccr.biomedcentral.com) (jeccr.biomedcentral.com). The fact that CHRAC1 has been confirmed as a key gene in a recurrent breast cancer amplification (jeccr.biomedcentral.com) and that its loss impairs tumor growth (pmc.ncbi.nlm.nih.gov) makes it an exciting candidate for targeted research. Therapies that inhibit chromatin remodelers (sometimes termed “chromatin therapeutics”) could potentially exploit the cancer-specific dependency on CHRAC1. However, given CHRAC1’s essential role in normal cells, such approaches would require precision to avoid toxicity.

In conclusion, CHRAC1 is a multifaceted chromatin protein whose primary role is to support and enhance the machines that reorganize and replicate our genome. It anchors remodelers to nucleosomes, helping slide and assemble histones, and intersects with the replication fork to maintain chromatin continuity. Its activity is confined to the nucleus, where it safeguards genomic information flow – from DNA packaging to gene expression and replication. Ongoing research, especially in oncology, continues to shed light on CHRAC1’s importance. As our understanding grows, CHRAC1 stands as a compelling example of how even the smallest protein components of chromatin complexes can have broad impacts on cell fate and function, making it both a fundamental piece of the chromatin infrastructure and a potential node to target in diseases of genome dysregulation.

References:

• Bickmore WA & Varga-Weisz PD. (2000). EMBO J. 19(11):3377–3387. – Identification of human CHRAC complex containing hACF1 and two novel histone-fold proteins (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
• Kukimoto I et al. (2004). Molecular Cell 13(2):265–277. – Demonstrated that the CHRAC-15/17 histone-fold protein pair (human CHRAC1/POLE3) enhances ATP-dependent nucleosome sliding and assembly by ACF (jeccr.biomedcentral.com) (jeccr.biomedcentral.com).
• Pursell ZF & Kunkel TA. (2008). Prog. Nucleic Acid Res. Mol. Biol. 82:101–145. – Comprehensive review of DNA polymerase ε; discusses shared subunits between Pol ε and chromatin remodelers and their role in chromatin binding (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
• Clapier CR et al. (2017). Nat. Rev. Mol. Cell Biol. 18(7):407–422. – Review on mechanisms of chromatin remodeling; highlights the function of histone-fold subunits in remodeler targeting and activity (pmc.ncbi.nlm.nih.gov).
• Mahmood SF et al. (2014). Carcinogenesis 35(3):670–682. – RNAi screen finding CHRAC1 as a driver gene within chromosome 8q24.3 amplification in breast cancer (jeccr.biomedcentral.com) (jeccr.biomedcentral.com).
• Li S et al. (2024). PeerJ 12:e16752 (Published Jan 10, 2024). – Study showing CHRAC1 promotes YAP-mediated transcription in breast and cervical cancer; CHRAC1 knockdown inhibits tumor growth and correlates with better patient prognosis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
• Song Y et al. (2021). J. Exp. Clin. Cancer Res. 40:346 (Published Nov 4, 2021). – Review on ISWI chromatin remodeling complexes in cancer; reports frequent upregulation of CHRAC1 (with BAZ1A and POLE3) in tumors and discusses their potential oncogenic roles (jeccr.biomedcentral.com) (jeccr.biomedcentral.com).
• Smith OK et al. (2018). Mol. Cell 70:707–721.e7. – Showed that the POLE3–POLE4 subcomplex of Pol ε acts as a histone H3–H4 chaperone during DNA replication, linking polymerase action to nucleosome assembly (pubmed.ncbi.nlm.nih.gov). (This provides insight into the function of the related CHRAC1–POLE3 pair in chromatin context.)

Citations

1. AnnotationURLCitation(end_index=705, start_index=498, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Chromatin%20remodeling%20complexes%20containing%20the,complexes%20via%20association%20with%20different')
2. AnnotationURLCitation(end_index=1066, start_index=879, title='The histone-fold protein complex CHRAC-15/17 enhances nucleosome sliding and assembly mediated by ACF. | BioGRID', type='url_citation', url='https://thebiogrid.org/114419/publication/the-histone-fold-protein-complex-chrac-1517-enhances-nucleosome-sliding-and-assembly-mediated-by-acf.html#:~:text=Read%20More')
3. AnnotationURLCitation(end_index=1239, start_index=1067, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=match%20at%20L373%20Furthermore%2C%20CHRAC1,CHRAC%20complex%20%5B63')
4. AnnotationURLCitation(end_index=1418, start_index=1316, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=,DNA%20Interaction')
5. AnnotationURLCitation(end_index=1780, start_index=1652, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=match%20at%20L914%20%CE%B5%20and,linked%20to')
6. AnnotationURLCitation(end_index=1950, start_index=1781, title='POLE3-POLE4 Is a Histone H3-H4 Chaperone that Maintains Chromatin Integrity during DNA Replication - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/30217558/#:~:text=Maintenance%20of%20epigenetic%20integrity%20relies,to%20selectively%20bind%20to%20histones')
7. AnnotationURLCitation(end_index=2303, start_index=2161, title='CHRAC1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000104472-CHRAC1#:~:text=Subcellular%20location,i%7D%20Low%20tissue%20specificity')
8. AnnotationURLCitation(end_index=2604, start_index=2462, title='CHRAC1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000104472-CHRAC1#:~:text=Subcellular%20location,i%7D%20Low%20tissue%20specificity')
9. AnnotationURLCitation(end_index=3287, start_index=3037, title='The histone-fold protein complex CHRAC-15/17 enhances nucleosome sliding and assembly mediated by ACF. | BioGRID', type='url_citation', url='https://thebiogrid.org/114419/publication/the-histone-fold-protein-complex-chrac-1517-enhances-nucleosome-sliding-and-assembly-mediated-by-acf.html#:~:text=%5BACF%5D%29%20associates%20with%20histone,17%20interacts%20with%20another')
10. AnnotationURLCitation(end_index=3460, start_index=3288, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=match%20at%20L373%20Furthermore%2C%20CHRAC1,CHRAC%20complex%20%5B63')
11. AnnotationURLCitation(end_index=3650, start_index=3548, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=,DNA%20Interaction')
12. AnnotationURLCitation(end_index=3927, start_index=3825, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=,DNA%20Interaction')
13. AnnotationURLCitation(end_index=4253, start_index=4125, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=match%20at%20L914%20%CE%B5%20and,linked%20to')
14. AnnotationURLCitation(end_index=4596, start_index=4468, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=match%20at%20L914%20%CE%B5%20and,linked%20to')
15. AnnotationURLCitation(end_index=4950, start_index=4795, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=match%20at%20L922%20propagate%20a,%CE%B5%20through%20Dpb4%2C%20with%20a')
16. AnnotationURLCitation(end_index=5695, start_index=5504, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=BAZ1A%20forms%20ACF%20complexes%20together,the%20ACF%20complex%2C%20BAZ1A%20stimulates')
17. AnnotationURLCitation(end_index=6007, start_index=5833, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=%28SMARCA1%2F5%20and%20RSF1%29%2C%20ACF,5%20%28SMARCA1%2F5%2C%20BAZ2B')
18. AnnotationURLCitation(end_index=6180, start_index=6008, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=match%20at%20L373%20Furthermore%2C%20CHRAC1,CHRAC%20complex%20%5B63')
19. AnnotationURLCitation(end_index=6573, start_index=6323, title='The histone-fold protein complex CHRAC-15/17 enhances nucleosome sliding and assembly mediated by ACF. | BioGRID', type='url_citation', url='https://thebiogrid.org/114419/publication/the-histone-fold-protein-complex-chrac-1517-enhances-nucleosome-sliding-and-assembly-mediated-by-acf.html#:~:text=%5BACF%5D%29%20associates%20with%20histone,17%20interacts%20with%20another')
20. AnnotationURLCitation(end_index=6849, start_index=6688, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=remodeling%20complexes%20came%20with%20the,of%20human%20Pol%20%CE%B5%2C%20p12')
21. AnnotationURLCitation(end_index=6978, start_index=6850, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=match%20at%20L914%20%CE%B5%20and,linked%20to')
22. AnnotationURLCitation(end_index=7337, start_index=7180, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=subunits%2C%20called%20p15%20and%20p17,of%20human%20Pol%20%CE%B5%2C%20p12')
23. AnnotationURLCitation(end_index=7494, start_index=7338, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=homology%20to%20the%20unique%20HFM,the%20two%20complexes%2C%20but%20this')
24. AnnotationURLCitation(end_index=7870, start_index=7709, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=remodeling%20complexes%20came%20with%20the,of%20human%20Pol%20%CE%B5%2C%20p12')
25. AnnotationURLCitation(end_index=8042, start_index=7871, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=purified%20CHRAC%20in%20multiple%20species,that%20the%20human%20p12%2Fp17%20heterodimer')
26. AnnotationURLCitation(end_index=8291, start_index=8130, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=remodeling%20complexes%20came%20with%20the,of%20human%20Pol%20%CE%B5%2C%20p12')
27. AnnotationURLCitation(end_index=8448, start_index=8292, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=homology%20to%20the%20unique%20HFM,the%20two%20complexes%2C%20but%20this')
28. AnnotationURLCitation(end_index=8860, start_index=8673, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=together%20with%20Ioc2%20and%20Ioc4,activation%20until%20signal%20thresholds%20are')
29. AnnotationURLCitation(end_index=9627, start_index=9455, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=match%20at%20L373%20Furthermore%2C%20CHRAC1,CHRAC%20complex%20%5B63')
30. AnnotationURLCitation(end_index=9808, start_index=9628, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Furthermore%2C%20CHRAC1%20and%20POLE3%20interaction,CHRAC%20complex%20%5B63')
31. AnnotationURLCitation(end_index=10241, start_index=10069, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=match%20at%20L373%20Furthermore%2C%20CHRAC1,CHRAC%20complex%20%5B63')
32. AnnotationURLCitation(end_index=10422, start_index=10242, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Furthermore%2C%20CHRAC1%20and%20POLE3%20interaction,CHRAC%20complex%20%5B63')
33. AnnotationURLCitation(end_index=10835, start_index=10585, title='The histone-fold protein complex CHRAC-15/17 enhances nucleosome sliding and assembly mediated by ACF. | BioGRID', type='url_citation', url='https://thebiogrid.org/114419/publication/the-histone-fold-protein-complex-chrac-1517-enhances-nucleosome-sliding-and-assembly-mediated-by-acf.html#:~:text=%5BACF%5D%29%20associates%20with%20histone,17%20interacts%20with%20another')
34. AnnotationURLCitation(end_index=11008, start_index=10836, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=match%20at%20L373%20Furthermore%2C%20CHRAC1,CHRAC%20complex%20%5B63')
35. AnnotationURLCitation(end_index=11368, start_index=11118, title='The histone-fold protein complex CHRAC-15/17 enhances nucleosome sliding and assembly mediated by ACF. | BioGRID', type='url_citation', url='https://thebiogrid.org/114419/publication/the-histone-fold-protein-complex-chrac-1517-enhances-nucleosome-sliding-and-assembly-mediated-by-acf.html#:~:text=%5BACF%5D%29%20associates%20with%20histone,17%20interacts%20with%20another')
36. AnnotationURLCitation(end_index=11909, start_index=11740, title='POLE3-POLE4 Is a Histone H3-H4 Chaperone that Maintains Chromatin Integrity during DNA Replication - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/30217558/#:~:text=Maintenance%20of%20epigenetic%20integrity%20relies,to%20selectively%20bind%20to%20histones')
37. AnnotationURLCitation(end_index=12299, start_index=12130, title='POLE3-POLE4 Is a Histone H3-H4 Chaperone that Maintains Chromatin Integrity during DNA Replication - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/30217558/#:~:text=Maintenance%20of%20epigenetic%20integrity%20relies,to%20selectively%20bind%20to%20histones')
38. AnnotationURLCitation(end_index=12743, start_index=12615, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=match%20at%20L914%20%CE%B5%20and,linked%20to')
39. AnnotationURLCitation(end_index=13842, start_index=13680, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=match%20at%20L879%20CHRAC%20was,disorganized%20nucleosomes%20formed%20in%20the')
40. AnnotationURLCitation(end_index=14232, start_index=14060, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=CHRAC%20was%20initially%20purified%20from,disorganized%20nucleosomes%20formed%20in%20the')
41. AnnotationURLCitation(end_index=14665, start_index=14458, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Chromatin%20remodeling%20complexes%20containing%20the,complexes%20via%20association%20with%20different')
42. AnnotationURLCitation(end_index=14857, start_index=14666, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=BAZ1A%20forms%20ACF%20complexes%20together,the%20ACF%20complex%2C%20BAZ1A%20stimulates')
43. AnnotationURLCitation(end_index=15229, start_index=15057, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=match%20at%20L373%20Furthermore%2C%20CHRAC1,CHRAC%20complex%20%5B63')
44. AnnotationURLCitation(end_index=15410, start_index=15230, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Furthermore%2C%20CHRAC1%20and%20POLE3%20interaction,CHRAC%20complex%20%5B63')
45. AnnotationURLCitation(end_index=15737, start_index=15565, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=match%20at%20L373%20Furthermore%2C%20CHRAC1,CHRAC%20complex%20%5B63')
46. AnnotationURLCitation(end_index=16515, start_index=16308, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Chromatin%20remodeling%20complexes%20containing%20the,complexes%20via%20association%20with%20different')
47. AnnotationURLCitation(end_index=16975, start_index=16825, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=In%20the%20current%20study%2C%20we,of%20YAP%20target%20genes%20in')
48. AnnotationURLCitation(end_index=17152, start_index=16976, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=Hippo%20pathway%2C%20thereby%20promoting%20tumorigenesis,YAP%20in%20breast%20and%20cervical')
49. AnnotationURLCitation(end_index=17511, start_index=17361, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=In%20the%20current%20study%2C%20we,of%20YAP%20target%20genes%20in')
50. AnnotationURLCitation(end_index=17669, start_index=17512, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=match%20at%20L53%20Hippo%20pathway%2C,YAP%20in%20breast%20and%20cervical')
51. AnnotationURLCitation(end_index=18023, start_index=17873, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=In%20the%20current%20study%2C%20we,of%20YAP%20target%20genes%20in')
52. AnnotationURLCitation(end_index=18200, start_index=18024, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=Hippo%20pathway%2C%20thereby%20promoting%20tumorigenesis,YAP%20in%20breast%20and%20cervical')
53. AnnotationURLCitation(end_index=19122, start_index=18953, title='POLE3-POLE4 Is a Histone H3-H4 Chaperone that Maintains Chromatin Integrity during DNA Replication - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/30217558/#:~:text=Maintenance%20of%20epigenetic%20integrity%20relies,to%20selectively%20bind%20to%20histones')
54. AnnotationURLCitation(end_index=19867, start_index=19702, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=Evidence%20from%20metazoan%20cells%20indicates,and%20BrdU%2C%20during%20S%20phase')
55. AnnotationURLCitation(end_index=20352, start_index=20196, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=has%20been%20found%20in%20a,during%20which%20time%20heterochromatin%20is')
56. AnnotationURLCitation(end_index=20690, start_index=20528, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=propagate%20a%20silenced%20state%2C%20or,%CE%B5%20through%20Dpb4%2C%20with%20a')
57. AnnotationURLCitation(end_index=20847, start_index=20691, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=has%20been%20found%20in%20a,during%20which%20time%20heterochromatin%20is')
58. AnnotationURLCitation(end_index=21225, start_index=21064, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=this%20region%20in%20opposition%20to,silencing%20and%20activation%20in%20this')
59. AnnotationURLCitation(end_index=21606, start_index=21451, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=match%20at%20L922%20propagate%20a,%CE%B5%20through%20Dpb4%2C%20with%20a')
60. AnnotationURLCitation(end_index=21769, start_index=21607, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=propagate%20a%20silenced%20state%2C%20or,%CE%B5%20through%20Dpb4%2C%20with%20a')
61. AnnotationURLCitation(end_index=22305, start_index=22136, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=CHRAC%20may%20also%20contribute%2C%20directly,to%20rearrange%20the%20nucleosomes%20on')
62. AnnotationURLCitation(end_index=23113, start_index=22932, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=In%20normal%20cells%2C%20BAZ1A%20is,strand%20breaks%20%28DSBs%29%20and%20DSB')
63. AnnotationURLCitation(end_index=23300, start_index=23114, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=the%20KU70%2F80%20complex%20and%20formation,disruption%20of%20the%20ACF%20complex')
64. AnnotationURLCitation(end_index=23856, start_index=23700, title='The loss of DNA polymerase epsilon accessory subunits POLE3–POLE4 leads to BRCA1-independent PARP inhibitor sensitivity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11229324/#:~:text=The%20loss%20of%20DNA%20polymerase,the%20levels%20of%20POLE3%2C%20POLE4')
65. AnnotationURLCitation(end_index=23989, start_index=23857, title='The loss of DNA polymerase epsilon accessory subunits POLE3–POLE4 leads to BRCA1-independent PARP inhibitor sensitivity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11229324/#:~:text=Figure%201,the%20levels%20of%20POLE3%2C%20POLE4')
66. AnnotationURLCitation(end_index=25213, start_index=25071, title='CHRAC1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000104472-CHRAC1#:~:text=Subcellular%20location,i%7D%20Low%20tissue%20specificity')
67. AnnotationURLCitation(end_index=25774, start_index=25609, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=Evidence%20from%20metazoan%20cells%20indicates,and%20BrdU%2C%20during%20S%20phase')
68. AnnotationURLCitation(end_index=26088, start_index=25932, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=has%20been%20found%20in%20a,during%20which%20time%20heterochromatin%20is')
69. AnnotationURLCitation(end_index=26575, start_index=26442, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=activator%20Yes,were%20used%20to%20analyze%20the')
70. AnnotationURLCitation(end_index=26726, start_index=26576, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=In%20the%20current%20study%2C%20we,of%20YAP%20target%20genes%20in')
71. AnnotationURLCitation(end_index=27593, start_index=27451, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=some%20oncogenic%20genes%20,resistant')
72. AnnotationURLCitation(end_index=27919, start_index=27777, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=some%20oncogenic%20genes%20,resistant')
73. AnnotationURLCitation(end_index=28101, start_index=27920, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=siRNA%20screen%20identifies%20RAD21%2C%20EIF3H%2C,2014%3B35%3A670%E2%80%9382')
74. AnnotationURLCitation(end_index=28777, start_index=28593, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Through%20TCGA%20database%20analysis%2C%20we,kinds%20of%20tumors%2C%20such%20as')
75. AnnotationURLCitation(end_index=28962, start_index=28778, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Through%20TCGA%20database%20analysis%2C%20we,kinds%20of%20tumors%2C%20such%20as')
76. AnnotationURLCitation(end_index=29323, start_index=29139, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Through%20TCGA%20database%20analysis%2C%20we,kinds%20of%20tumors%2C%20such%20as')
77. AnnotationURLCitation(end_index=29506, start_index=29324, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=of%20abnormal%20copy%20numbers%20in,ESCC%2C%20while%20this%20region%20harbors')
78. AnnotationURLCitation(end_index=30033, start_index=29903, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=match%20at%20L108%20addition%2C%20CHRAC1,2021')
79. AnnotationURLCitation(end_index=30647, start_index=30497, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=In%20the%20current%20study%2C%20we,of%20YAP%20target%20genes%20in')
80. AnnotationURLCitation(end_index=30824, start_index=30648, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=Hippo%20pathway%2C%20thereby%20promoting%20tumorigenesis,YAP%20in%20breast%20and%20cervical')
81. AnnotationURLCitation(end_index=31170, start_index=31020, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=In%20the%20current%20study%2C%20we,of%20YAP%20target%20genes%20in')
82. AnnotationURLCitation(end_index=31566, start_index=31409, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=match%20at%20L53%20Hippo%20pathway%2C,YAP%20in%20breast%20and%20cervical')
83. AnnotationURLCitation(end_index=32959, start_index=32775, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Through%20TCGA%20database%20analysis%2C%20we,kinds%20of%20tumors%2C%20such%20as')
84. AnnotationURLCitation(end_index=33142, start_index=32960, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=of%20abnormal%20copy%20numbers%20in,ESCC%2C%20while%20this%20region%20harbors')
85. AnnotationURLCitation(end_index=33713, start_index=33506, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Chromatin%20remodeling%20complexes%20containing%20the,complexes%20via%20association%20with%20different')
86. AnnotationURLCitation(end_index=33905, start_index=33714, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=BAZ1A%20forms%20ACF%20complexes%20together,the%20ACF%20complex%2C%20BAZ1A%20stimulates')
87. AnnotationURLCitation(end_index=34242, start_index=34094, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=Two%20yeast%20homologs%20of%20ISWI%2C,for%20any%20of%20the%20HFM')
88. AnnotationURLCitation(end_index=34399, start_index=34243, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=has%20been%20found%20in%20a,during%20which%20time%20heterochromatin%20is')
89. AnnotationURLCitation(end_index=34759, start_index=34603, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=homology%20to%20the%20unique%20HFM,the%20two%20complexes%2C%20but%20this')
90. AnnotationURLCitation(end_index=34931, start_index=34760, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=purified%20CHRAC%20in%20multiple%20species,that%20the%20human%20p12%2Fp17%20heterodimer')
91. AnnotationURLCitation(end_index=35367, start_index=35205, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=propagate%20a%20silenced%20state%2C%20or,%CE%B5%20through%20Dpb4%2C%20with%20a')
92. AnnotationURLCitation(end_index=35524, start_index=35368, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=has%20been%20found%20in%20a,during%20which%20time%20heterochromatin%20is')
93. AnnotationURLCitation(end_index=36223, start_index=36086, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=chromatin%20accessibility%20complex%20subunit%201,In')
94. AnnotationURLCitation(end_index=36796, start_index=36612, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Through%20TCGA%20database%20analysis%2C%20we,kinds%20of%20tumors%2C%20such%20as')
95. AnnotationURLCitation(end_index=36979, start_index=36797, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=of%20abnormal%20copy%20numbers%20in,ESCC%2C%20while%20this%20region%20harbors')
96. AnnotationURLCitation(end_index=37387, start_index=37203, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Through%20TCGA%20database%20analysis%2C%20we,kinds%20of%20tumors%2C%20such%20as')
97. AnnotationURLCitation(end_index=37530, start_index=37388, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=some%20oncogenic%20genes%20,resistant')
98. AnnotationURLCitation(end_index=37771, start_index=37629, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=some%20oncogenic%20genes%20,resistant')
99. AnnotationURLCitation(end_index=37961, start_index=37811, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=In%20the%20current%20study%2C%20we,of%20YAP%20target%20genes%20in')
100. AnnotationURLCitation(end_index=39512, start_index=39340, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=CHRAC%20was%20initially%20purified%20from,disorganized%20nucleosomes%20formed%20in%20the')
101. AnnotationURLCitation(end_index=39674, start_index=39513, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=remodeling%20complexes%20came%20with%20the,of%20human%20Pol%20%CE%B5%2C%20p12')
102. AnnotationURLCitation(end_index=40057, start_index=39885, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=match%20at%20L373%20Furthermore%2C%20CHRAC1,CHRAC%20complex%20%5B63')
103. AnnotationURLCitation(end_index=40238, start_index=40058, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Furthermore%2C%20CHRAC1%20and%20POLE3%20interaction,CHRAC%20complex%20%5B63')
104. AnnotationURLCitation(end_index=40598, start_index=40470, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=match%20at%20L914%20%CE%B5%20and,linked%20to')
105. AnnotationURLCitation(end_index=40754, start_index=40599, title='DNA Polymerase ε: A Polymerase Of Unusual Size (and Complexity) - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3694787/#:~:text=match%20at%20L922%20propagate%20a,%CE%B5%20through%20Dpb4%2C%20with%20a')
106. AnnotationURLCitation(end_index=41101, start_index=40964, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=chromatin%20accessibility%20complex%20subunit%201,In')
107. AnnotationURLCitation(end_index=41411, start_index=41269, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=some%20oncogenic%20genes%20,resistant')
108. AnnotationURLCitation(end_index=41593, start_index=41412, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=siRNA%20screen%20identifies%20RAD21%2C%20EIF3H%2C,2014%3B35%3A670%E2%80%9382')
109. AnnotationURLCitation(end_index=41989, start_index=41839, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=In%20the%20current%20study%2C%20we,of%20YAP%20target%20genes%20in')
110. AnnotationURLCitation(end_index=42147, start_index=41990, title='Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10787542/#:~:text=match%20at%20L53%20Hippo%20pathway%2C,YAP%20in%20breast%20and%20cervical')
111. AnnotationURLCitation(end_index=42599, start_index=42415, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=Through%20TCGA%20database%20analysis%2C%20we,kinds%20of%20tumors%2C%20such%20as')
112. AnnotationURLCitation(end_index=42742, start_index=42600, title='The emerging role of ISWI chromatin remodeling complexes in cancer | Journal of Experimental & Clinical Cancer Research | Full Text', type='url_citation', url='https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02151-x#:~:text=some%20oncogenic%20genes%20,resistant')
113. AnnotationURLCitation(end_index=43127, start_index=42958, title='POLE3-POLE4 Is a Histone H3-H4 Chaperone that Maintains Chromatin Integrity during DNA Replication - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/30217558/#:~:text=Maintenance%20of%20epigenetic%20integrity%20relies,to%20selectively%20bind%20to%20histones')